China's HUTCHMED climbs as AstraZeneca applies for US cancer drug approval

HUTCHMED (China)

29/09/2026 03:22

** Shares of HUTCHMED (China) 0013.HK climb 4.1% to HK$23.1, their highest level since September 4
** Stock on track for its biggest one-day pct gain since September 21 
** HUTCHMED said on Tuesday that Anglo-Swedish drugmaker AstraZeneca AZN.L had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer
** ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca
** YTD, HUTCHMED's Hong Kong stock up 11%, Hang Seng Biotech Index .HSBIO up 14%


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))